RU2663141C2 - Анти-cxcr3 антитела - Google Patents

Анти-cxcr3 антитела Download PDF

Info

Publication number
RU2663141C2
RU2663141C2 RU2014134043A RU2014134043A RU2663141C2 RU 2663141 C2 RU2663141 C2 RU 2663141C2 RU 2014134043 A RU2014134043 A RU 2014134043A RU 2014134043 A RU2014134043 A RU 2014134043A RU 2663141 C2 RU2663141 C2 RU 2663141C2
Authority
RU
Russia
Prior art keywords
antibody
cxcr3
sequence
cells
fragment
Prior art date
Application number
RU2014134043A
Other languages
English (en)
Russian (ru)
Other versions
RU2014134043A (ru
Inventor
Мишель ЮД
Дженнифер ТЕДСТОУН
Трейси ЛОДИ
Карен Б. КАРТЕР
Тимоти Д. КОННОРС
Джейсон Роберт ПИНКНИ
Элизабет МАСТЕРДЖОН
Жуйинь ЧУ
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of RU2014134043A publication Critical patent/RU2014134043A/ru
Application granted granted Critical
Publication of RU2663141C2 publication Critical patent/RU2663141C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2014134043A 2012-01-20 2013-01-18 Анти-cxcr3 антитела RU2663141C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20
US61/588,936 2012-01-20
PCT/US2013/022280 WO2013109974A2 (en) 2012-01-20 2013-01-18 Anti-cxcr3 antibodies

Publications (2)

Publication Number Publication Date
RU2014134043A RU2014134043A (ru) 2016-03-20
RU2663141C2 true RU2663141C2 (ru) 2018-08-01

Family

ID=47633576

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014134043A RU2663141C2 (ru) 2012-01-20 2013-01-18 Анти-cxcr3 антитела

Country Status (26)

Country Link
US (4) US8865870B2 (enExample)
EP (1) EP2804878B1 (enExample)
JP (3) JP6352812B6 (enExample)
KR (2) KR102073034B1 (enExample)
CN (1) CN104507967B (enExample)
AR (1) AR090056A1 (enExample)
AU (1) AU2013209492B2 (enExample)
BR (1) BR112014017814A8 (enExample)
CA (1) CA2862222A1 (enExample)
CY (1) CY1121335T1 (enExample)
DK (1) DK2804878T3 (enExample)
ES (1) ES2698606T3 (enExample)
HR (1) HRP20181874T1 (enExample)
HU (1) HUE041900T2 (enExample)
IL (2) IL233694A0 (enExample)
LT (1) LT2804878T (enExample)
MX (1) MX359854B (enExample)
PL (1) PL2804878T3 (enExample)
PT (1) PT2804878T (enExample)
RS (1) RS58141B1 (enExample)
RU (1) RU2663141C2 (enExample)
SG (2) SG11201406762QA (enExample)
SI (1) SI2804878T1 (enExample)
TW (1) TWI596112B (enExample)
UY (1) UY34582A (enExample)
WO (1) WO2013109974A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
SG11201701382PA (en) 2014-08-22 2017-03-30 Sorrento Therapeutics Inc Antigen binding proteins that bind cxcr3
SG11201803567XA (en) 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
JP2020514273A (ja) * 2016-12-22 2020-05-21 サノフイＳａｎｏｆｉ 白斑症の処置のための抗ヒトｃｘｃｒ３抗体
UY37544A (es) * 2016-12-22 2018-07-31 Sanofi Sa Anticuerpos humanizados contra cxcr3 con actividad mermadora y métodos de uso de los mismos
CA3091311A1 (en) 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
CN116234572A (zh) * 2020-04-30 2023-06-06 安驰肿瘤公司 治疗性SIRPα抗体
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4301784A4 (en) * 2021-03-02 2025-01-01 NovaRock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4583878A1 (en) 2022-09-09 2025-07-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist
JP7784193B1 (ja) 2024-01-31 2025-12-11 株式会社エヌビィー健康研究所 抗体、核酸、細胞、及び医薬
WO2025185738A1 (zh) * 2024-03-08 2025-09-12 演生潮(北京)生物科技有限公司 靶向cxcr3的抗原结合蛋白及其应用
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
US6686175B1 (en) * 1996-09-10 2004-02-03 Theodor-Kocher Institute IP-10/MIG receptor designated CXCR3, nucleic acids, and methods of use therefor
RU2006102570A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Антитела и их применение
WO2008094942A2 (en) * 2007-02-01 2008-08-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against cxcr3
WO2010103517A1 (en) * 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE360689T1 (de) * 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
EP1631315B1 (en) 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
KR20070041781A (ko) 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
US20100130476A1 (en) 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
CN110655573B (zh) * 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686175B1 (en) * 1996-09-10 2004-02-03 Theodor-Kocher Institute IP-10/MIG receptor designated CXCR3, nucleic acids, and methods of use therefor
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
RU2006102570A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Антитела и их применение
WO2008094942A2 (en) * 2007-02-01 2008-08-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against cxcr3
WO2010103517A1 (en) * 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLARK-LEWIS I. et al., "Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its Ligands", J Biol Chem., 2003, 278(1):289-95. *

Also Published As

Publication number Publication date
TWI596112B (zh) 2017-08-21
JP2020072715A (ja) 2020-05-14
CN104507967A (zh) 2015-04-08
US9765144B2 (en) 2017-09-19
AR090056A1 (es) 2014-10-15
UY34582A (es) 2013-09-02
TW201335188A (zh) 2013-09-01
PT2804878T (pt) 2018-11-29
CA2862222A1 (en) 2013-07-25
SI2804878T1 (sl) 2018-12-31
JP2018166506A (ja) 2018-11-01
WO2013109974A3 (en) 2013-11-07
LT2804878T (lt) 2018-12-10
RS58141B1 (sr) 2019-02-28
MX359854B (es) 2018-10-12
IL233694A0 (en) 2014-09-30
SG11201406762QA (en) 2014-11-27
MX2014008728A (es) 2015-07-06
US8865870B2 (en) 2014-10-21
AU2013209492B2 (en) 2018-02-08
SG10201700735PA (en) 2017-02-27
AU2013209492A1 (en) 2014-08-14
RU2014134043A (ru) 2016-03-20
HK1208684A1 (en) 2016-03-11
PL2804878T3 (pl) 2019-03-29
US20140377806A1 (en) 2014-12-25
HUE041900T2 (hu) 2019-06-28
US20130251733A1 (en) 2013-09-26
KR20140116525A (ko) 2014-10-02
IL271697A (en) 2020-02-27
JP6352812B2 (ja) 2018-07-04
EP2804878B1 (en) 2018-08-22
HRP20181874T1 (hr) 2019-01-11
JP6646100B2 (ja) 2020-02-14
JP2015506945A (ja) 2015-03-05
BR112014017814A2 (enExample) 2017-06-20
JP6352812B6 (ja) 2018-08-08
CY1121335T1 (el) 2020-05-29
EP2804878A2 (en) 2014-11-26
ES2698606T3 (es) 2019-02-05
WO2013109974A2 (en) 2013-07-25
DK2804878T3 (en) 2018-12-17
KR102073034B1 (ko) 2020-02-05
US20190119391A1 (en) 2019-04-25
CN104507967B (zh) 2018-10-12
US20180086838A1 (en) 2018-03-29
KR20200014441A (ko) 2020-02-10
BR112014017814A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
JP6646100B2 (ja) 抗ｃｘｃｒ３抗体
US12258410B2 (en) Anti-SIRPα antibodies and methods of use thereof
CN108699153B (zh) Pd-l1的结合成员
CN110407941B (zh) Cd39的高亲和力抗体及其用途
KR20080080639A (ko) 항-ｏｘ40ｌ 항체 및 그의 사용 방법
JP7843824B2 (ja) 抗体および使用方法
WO2018119288A1 (en) Anti-human cxcr3 antibodies for treatment of vitiligo
HK1208684B (en) Anti-cxcr3 antibodies
EP3559036A1 (en) Anti-human cxcr3 antibodies for treatment of vitiligo
KR20260004605A (ko) 길항성 항-cd40 인간화 항체
TW202523698A (zh) 抗ｇｐｒｃ５ｄ抗體及組成物
IL324392A (en) Antibodies targeting human leukocyte antigen cathepsin g peptide complex
HK40016809A (en) High affinity antibodies to cd39 and uses thereof
HK40016809B (en) High affinity antibodies to cd39 and uses thereof